Physician profile
Peter G Roan
NPI 1326037342
$6,215.44
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,181 · 2020: $1,811 · 2021: $2,191 · 2022: $32.52.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $3,135.72 | 2019-2020 | |
| Medtronic, INC. | $1,977.99 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $273.23 | 2019-2021 | |
| Amgen INC. | $164.30 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $130.48 | 2019 | |
| Amarin Pharma, INC. | $124.63 | 2020 | |
| Pfizer INC. | $78.11 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $60.44 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $49.19 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $45.76 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $42.31 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $40.24 | 2019-2020 | |
| Irhythm Technologies, INC. | $23.05 | 2021 | |
| Chiesi USA, INC. | $16.80 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $15.99 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $13.80 | 2019 | |
| Preventice Services, LLC | $12.18 | 2021 | |
| United Therapeutics Corporation | $11.22 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Roan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.